Not yet recruiting NCT07312799
Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Treatment A(AD-2321), Treatment B(AD-2322), Treatment C(AD-2321+AD-2322).
- Who it may be relevant to
- Registry conditions: Hypertension. Basic parameters: 19 years — 64 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- South Korea
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Two-arm, Open-label, Single-sequence, Multiple-dose Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322 in Healthy Adult Volunteers
Overview
To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.
Interventions
- Drug Treatment A(AD-2321)
AD-2321 Oral Tablet - Drug Treatment B(AD-2322)
AD-2322 Oral Tablet - Drug Treatment C(AD-2321+AD-2322)
AD-2321 Oral Tablet+AD-2322 Oral Tablet
Primary outcome measures
- Area under the plasma concentration-time curve during dosing interval at steady state (AUCτ,ss) [Time frame: pre-dose (0hour) to 24 hours post-dose on Day 14]
- Maximum concentration of drug in plasma at steady state (Cmax,ss) [Time frame: pre-dose (0hour) to 24 hours post-dose on Day 14]
Eligibility criteria
Inclusion criteria
- Healthy adult volunteers aged ≥19 and <65 years at the time of the screening visit
- Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg/m² and 30.0 kg/m² at the time of the screening visit
Exclusion criteria
- Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
- Other exclusions applied
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
South Korea · 1 center
- H+ Yangji Hospital — Seoul
Identifiers
NCT: NCT07312799 · AD-232DDI